Medline

Forecast & Rating26 analysts currently cover Medline, with about 84.6% giving a positive rating — meaning they expect the stock to rise. The average price target is $50.65, about 29.5% upside from the current price of $39.12. Price targets span a fair range, indicating some disagreement among institutions. For you, this means most professionals who study Medline closely still see room for the stock to rise. Data as of Jul 30, 2026; for reference only and not investment advice.